• Recording of symptomatic or life threatening arrhythmia event [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  ECG monitoring is conducted until occurrence of symptomatic arrhythmia or life threatening arrhythmia but not longer than 14 days. Patients in the control group will have standard ECG Holter monitoring repeated 3 times unless arrhythmia is diagnosed earlier.
  
  

• Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale assessment against evidence of cardiac arrhythmia occurrence. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  Verification of patient self assessment based on the Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale against evidence of cardiac arrhythmia occurrence.
  
  
• Silent (asymptomatic) arrhythmia events incidence detection assessment [ Time Frame: 14 days ] [ Designated as safety issue: No ]

  Evaluation of silent (asymptomatic) arrhythmia events incidence which potentially could cause serious complications

  1. Atrial fibrillation
  2. Atrial flutter
  3. Atrial Tachycardia
  4. Ventricular tachycardia
  
  
• Evaluation of stroke and bleeding risk factors incidence [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  Evaluation of stroke and bleeding risk factors incidence based on scores proposed in the European Society of Cardiology (ESC) guidelines: CHADS2VASC2 and HAS-BLED.
  
  

Irregular and/or rapid beating of the heart called heart palpitations can occur in individuals without heart disease and the reasons for their palpitations are unknown. Together with heart palpitations silent arrhythmia may be present that could lead to serious complications (eg. stroke). In others, palpitations result from heart rhythm disturbances, sometimes life threatening. Standard diagnostic methods such as 24 hours Holter ECG monitoring or Event Holter do not guarantee early diagnosis of the arrhythmia. Prolonged heart rhythm recording and analysis using an automatic full disclosure telemetric device increase probability of arrhythmia diagnosis and early administration of applicable treatment. Study patients will be diagnosed using standard Holter ECG monitoring and 14 days telemetric full disclosure ECG monitoring. The full disclosure signal will be subsequently analyzed in the Event Monitoring mode by an independent consultant. Efficacy of Telemetric Monitoring in diagnosis of cardiac arrhythmia will be assessed in comparison with the standard Holter monitoring and Event Monitoring.